Cargando…

Should Sex Be Considered an Effect Modifier in the Evaluation of Influenza Vaccine Effectiveness?

We investigated sex as a potential modifier of influenza vaccine effectiveness (VE) between 2010–2011 and 2016–2017 in Canada. Overall VE was 49% (95% confidence interval [CI], 43% to 55%) for females and 38% (95% CI, 28% to 46%) for males (absolute difference [AD], 11%; P = .03). Sex differences we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chambers, Catharine, Skowronski, Danuta M, Rose, Caren, Serres, Gaston De, Winter, Anne-Luise, Dickinson, James A, Jassem, Agatha, Gubbay, Jonathan B, Fonseca, Kevin, Drews, Steven J, Charest, Hugues, Martineau, Christine, Petric, Martin, Krajden, Mel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6143149/ https://www.ncbi.nlm.nih.gov/pubmed/30263903 http://dx.doi.org/10.1093/ofid/ofy211

Ejemplares similares

Vaccine Effectiveness Against Lineage-matched and -mismatched Influenza B Viruses Across 8 Seasons in Canada, 2010–2011 to 2017–2018
por: Skowronski, Danuta M, et al.
Publicado: (2019)

Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017
por: Skowronski, Danuta M, et al.
Publicado: (2017)

Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018
por: Skowronski, Danuta M, et al.
Publicado: (2018)

Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015–2016 Season in Canada
por: Skowronski, Danuta M, et al.
Publicado: (2017)

Influenza Vaccine Does Not Increase the Risk of Coronavirus or Other Noninfluenza Respiratory Viruses: Retrospective Analysis From Canada, 2010–2011 to 2016–2017
por: Skowronski, Danuta M, et al.
Publicado: (2020)

Age-Related Differences in Influenza B Infection by Lineage in a Community-Based Sentinel System, 2010–2011 to 2015–2016, Canada
por: Skowronski, Danuta M, et al.
Publicado: (2017)

Influenza Vaccine Effectiveness by A(H3N2) Phylogenetic Subcluster and Prior Vaccination History: 2016–2017 and 2017–2018 Epidemics in Canada
por: Skowronski, Danuta M, et al.
Publicado: (2020)

Children under 10 years of age were more affected by the 2018/19 influenza A(H1N1)pdm09 epidemic in Canada: ‎possible cohort effect following the 2009 influenza pandemic
por: Skowronski, Danuta M, et al.
Publicado: (2019)

A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014–2015 Season
por: Skowronski, Danuta M., et al.
Publicado: (2016)

Paradoxical clade- and age-specific vaccine effectiveness during the 2018/19 influenza A(H3N2) epidemic in Canada: potential imprint-regulated effect of vaccine (I-REV)
por: Skowronski, Danuta M, et al.
Publicado: (2019)

Interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza A and B viruses, Canada, February 2020
por: Skowronski, Danuta M, et al.
Publicado: (2020)

Low 2012–13 Influenza Vaccine Effectiveness Associated with Mutation in the Egg-Adapted H3N2 Vaccine Strain Not Antigenic Drift in Circulating Viruses
por: Skowronski, Danuta M., et al.
Publicado: (2014)

Influenza vaccine effectiveness against A(H3N2) during the delayed 2021/22 epidemic in Canada
por: Kim, Shinhye, et al.
Publicado: (2022)

Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23
por: Skowronski, Danuta M, et al.
Publicado: (2023)

Interim estimates of 2018/19 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, January 2019
por: Skowronski, Danuta M, et al.
Publicado: (2019)

Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009
por: Skowronski, Danuta M, et al.
Publicado: (2011)

Influenza Classification Suite: An automated Galaxy workflow for rapid influenza sequence analysis
por: Eisler, Diane, et al.
Publicado: (2020)

Case series of rash associated with influenza B in school children
por: Skowronski, Danuta M, et al.
Publicado: (2015)

Mid-Season Estimates of Influenza Vaccine Effectiveness against Influenza A(H3N2) Hospitalization in the Elderly in Quebec, Canada, January 2015
por: Gilca, Rodica, et al.
Publicado: (2015)

Role of Egg-adaptation Mutations in Low Influenza A(H3N2) Vaccine Effectiveness During the 2012–2013 Season
por: Skowronski, Danuta M, et al.
Publicado: (2018)

Avian Influenza A(H7N9) Virus Infection in 2 Travelers Returning from China to Canada, January 2015
por: Skowronski, Danuta M., et al.
Publicado: (2016)

Other Respiratory Viruses Are Important Contributors to Adult Respiratory Hospitalizations and Mortality Even During Peak Weeks of the Influenza Season
por: Gilca, Rodica, et al.
Publicado: (2014)

Caution Required in the Use of Administrative Data and General Laboratory Submissions for Influenza Vaccine Effectiveness Estimation
por: Skowronski, Danuta M, et al.
Publicado: (2019)

Ecological Fallacy, Nonspecific Outcomes, and the Attribution of Disproportionate Vaccine Benefits
por: De Serres, Gaston, et al.
Publicado: (2018)

Evidence in a Cluster Randomized Controlled Trial of Increased 2009 Pandemic Risk Associated With 2008–2009 Seasonal Influenza Vaccine Receipt
por: Skowronski, Danuta M, et al.
Publicado: (2019)

Age-Associated Seroprevalence of Coronavirus Antibodies: Population-Based Serosurveys in 2013 and 2020, British Columbia, Canada
por: Tanunliong, Guadalein, et al.
Publicado: (2022)

Influenza Vaccination of Healthcare Workers: Critical Analysis of the Evidence for Patient Benefit Underpinning Policies of Enforcement
por: De Serres, Gaston, et al.
Publicado: (2017)

SARS-CoV-2 mRNA Vaccine Effectiveness in Health Care Workers by Dosing Interval and Time Since Vaccination: Test-Negative Design, British Columbia, Canada
por: El Adam, Shiraz, et al.
Publicado: (2022)

Single-dose mRNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Including Alpha and Gamma Variants: A Test-negative Design in Adults 70 Years and Older in British Columbia, Canada
por: Skowronski, Danuta M, et al.
Publicado: (2021)

Contagious Period for Pandemic (H1N1) 2009
por: De Serres, Gaston, et al.
Publicado: (2010)

Adverse events following immunisation with four-component meningococcal serogroup B vaccine (4CMenB): interaction with co-administration of routine infant vaccines and risk of recurrence in European randomised controlled trials
por: Zafack, Joseline Guetsop, et al.
Publicado: (2019)

Respiratory syncytial virus contributes to more severe respiratory morbidity than influenza in children < 2 years during seasonal influenza peaks
por: Amini, Rachid, et al.
Publicado: (2019)

Association between the 2008–09 Seasonal Influenza Vaccine and Pandemic H1N1 Illness during Spring–Summer 2009: Four Observational Studies from Canada
por: Skowronski, Danuta M., et al.
Publicado: (2010)

Dramatic reduction in hepatitis B through school-based immunization without a routine infant program in a low endemicity region
por: Porgo, Teegwendé Valérie, et al.
Publicado: (2015)

O17 Detection of influenza A virus resistance to oseltamivir by a single nucleotide polymorphism-based assay
por: Mak, A., et al.
Publicado: (2009)

BNT162b2 Effectiveness Against Delta and Omicron Variants of Severe Acute Respiratory Syndrome Coronavirus 2 in Adolescents Aged 12–17 Years, by Dosing Interval and Duration
por: Ionescu, Iulia G, et al.
Publicado: (2023)

Community‐acquired respiratory viruses and co‐infection among patients of Ontario sentinel practices, April 2009 to February 2010
por: Peci, Adriana, et al.
Publicado: (2012)

Comparative Single-Dose mRNA and ChAdOx1 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2, Including Variants of Concern: Test-Negative Design, British Columbia, Canada
por: Skowronski, Danuta M, et al.
Publicado: (2022)

Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada
por: Gilca, Rodica, et al.
Publicado: (2020)

Modeling Control Strategies of Respiratory Pathogens
por: Pourbohloul, Babak, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_6veqr930kfak70aago293jubko